Fennec Pharmaceuticals Inc.
FRX.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 72.64% | 73.84% | 78.69% | 32.91% | -65.52% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 72.64% | 73.84% | 78.69% | 32.91% | -65.52% |
| Cost of Revenue | 52.82% | 163.68% | -51.36% | 59.05% | -32.18% |
| Gross Profit | 73.53% | 65.56% | 110.11% | 30.52% | -66.25% |
| SG&A Expenses | 60.67% | 78.71% | 11.57% | -1.96% | -17.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 59.29% | 84.34% | 3.90% | 0.67% | -17.84% |
| Operating Income | 85.27% | -173.45% | 96.37% | 45.78% | -105.88% |
| Income Before Tax | 117.25% | -188.95% | 88.88% | 43.24% | -109.08% |
| Income Tax Expenses | -- | -70.96% | -- | -- | -- |
| Earnings from Continuing Operations | 117.25% | -141.16% | 88.88% | 43.24% | -109.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 117.25% | -141.16% | 88.88% | 43.24% | -109.08% |
| EBIT | 85.27% | -173.45% | 96.37% | 45.78% | -105.88% |
| EBITDA | 88.11% | -178.11% | 96.85% | 46.00% | -105.41% |
| EPS Basic | 113.98% | -112.45% | 89.07% | 44.00% | -108.89% |
| Normalized Basic EPS | 114.02% | -50.99% | 89.08% | 43.98% | -108.89% |
| EPS Diluted | 113.98% | -89.40% | 89.10% | 44.00% | -110.29% |
| Normalized Diluted EPS | 113.26% | -50.99% | 89.08% | 43.98% | -110.24% |
| Average Basic Shares Outstanding | 24.51% | 13.53% | 1.89% | 1.34% | 1.97% |
| Average Diluted Shares Outstanding | 28.90% | 13.53% | 1.89% | 1.34% | -11.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |